Free Trial

Biomerica (BMRA) Competitors

Biomerica logo
$3.40 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$3.42 +0.02 (+0.44%)
As of 07:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BMRA vs. CLNN, SONN, ENLV, ALLK, GBIO, DYAI, OVID, DARE, NRSN, and MIRA

Should you be buying Biomerica stock or one of its competitors? The main competitors of Biomerica include Clene (CLNN), Sonnet BioTherapeutics (SONN), Enlivex Therapeutics (ENLV), Allakos (ALLK), Generation Bio (GBIO), Dyadic International (DYAI), Ovid Therapeutics (OVID), Dare Bioscience (DARE), NeuroSense Therapeutics (NRSN), and MIRA Pharmaceuticals (MIRA). These companies are all part of the "pharmaceutical products" industry.

Biomerica vs. Its Competitors

Biomerica (NASDAQ:BMRA) and Clene (NASDAQ:CLNN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, analyst recommendations, earnings, dividends and profitability.

Biomerica has a beta of 0.35, indicating that its stock price is 65% less volatile than the S&P 500. Comparatively, Clene has a beta of 0.55, indicating that its stock price is 45% less volatile than the S&P 500.

Biomerica has a net margin of -85.42% compared to Clene's net margin of -8,306.00%. Clene's return on equity of 0.00% beat Biomerica's return on equity.

Company Net Margins Return on Equity Return on Assets
Biomerica-85.42% -85.90% -61.06%
Clene -8,306.00%N/A -105.11%

Clene has a consensus price target of $40.00, indicating a potential upside of 947.12%. Given Clene's stronger consensus rating and higher probable upside, analysts plainly believe Clene is more favorable than Biomerica.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biomerica
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Clene
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
3.17

In the previous week, Clene had 1 more articles in the media than Biomerica. MarketBeat recorded 1 mentions for Clene and 0 mentions for Biomerica. Biomerica's average media sentiment score of 1.87 beat Clene's score of 0.93 indicating that Biomerica is being referred to more favorably in the media.

Company Overall Sentiment
Biomerica Very Positive
Clene Positive

Biomerica has higher revenue and earnings than Clene. Biomerica is trading at a lower price-to-earnings ratio than Clene, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biomerica$5.68M1.52-$5.98M-$2.32-1.47
Clene$340K92.92-$39.40M-$4.04-0.95

22.3% of Biomerica shares are owned by institutional investors. Comparatively, 23.3% of Clene shares are owned by institutional investors. 15.0% of Biomerica shares are owned by company insiders. Comparatively, 35.3% of Clene shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Clene beats Biomerica on 11 of the 17 factors compared between the two stocks.

Get Biomerica News Delivered to You Automatically

Sign up to receive the latest news and ratings for BMRA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BMRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BMRA vs. The Competition

MetricBiomericaMED IndustryMedical SectorNASDAQ Exchange
Market Cap$8.66M$2.46B$5.54B$9.41B
Dividend YieldN/A1.80%3.75%4.03%
P/E Ratio-1.474.4521.0120.09
Price / Sales1.52709.89433.8199.01
Price / CashN/A164.7736.1658.27
Price / Book1.095.008.125.65
Net Income-$5.98M$30.99M$3.25B$257.91M
7 Day Performance7.94%1.69%0.97%2.09%
1 Month Performance3.66%9.20%7.36%11.13%
1 Year Performance28.79%-1.25%31.31%18.40%

Biomerica Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BMRA
Biomerica
1.3149 of 5 stars
$3.40
flat
N/A+15.1%$8.66M$5.68M-1.4760Positive News
CLNN
Clene
3.4715 of 5 stars
$3.73
+3.9%
$40.00
+972.4%
-18.6%$30.85M$340K-0.92100Analyst Forecast
SONN
Sonnet BioTherapeutics
3.787 of 5 stars
$9.64
+86.5%
$20.00
+107.5%
+8.2%$30.56M$20K0.0010Gap Down
High Trading Volume
ENLV
Enlivex Therapeutics
2.7186 of 5 stars
$1.28
flat
$10.00
+681.3%
-13.7%$30.27MN/A-1.9470Positive News
ALLK
Allakos
3.3852 of 5 stars
$0.33
flat
$2.00
+507.7%
N/A$29.74MN/A-0.16190
GBIO
Generation Bio
3.8544 of 5 stars
$0.44
+13.9%
$7.33
+1,566.7%
-82.8%$29.50M$19.89M-0.41150News Coverage
Analyst Forecast
Stock Split
Gap Down
High Trading Volume
DYAI
Dyadic International
3.0328 of 5 stars
$0.97
-1.9%
$6.00
+518.6%
-31.5%$29.19M$3.34M-4.857Positive News
Gap Down
OVID
Ovid Therapeutics
4.6769 of 5 stars
$0.40
-2.0%
$3.13
+687.4%
-53.0%$28.22M$570K-1.1360Gap Up
DARE
Dare Bioscience
1.8546 of 5 stars
$3.09
+22.6%
$12.00
+288.3%
-28.2%$27.35M$10K-18.1830High Trading Volume
NRSN
NeuroSense Therapeutics
2.5015 of 5 stars
$2.00
-3.4%
$14.00
+600.0%
+150.1%$27.33MN/A-3.7010
MIRA
MIRA Pharmaceuticals
2.5101 of 5 stars
$1.54
+20.3%
$14.00
+809.1%
+146.3%$26.06MN/A-3.022Positive News
High Trading Volume

Related Companies and Tools


This page (NASDAQ:BMRA) was last updated on 7/18/2025 by MarketBeat.com Staff
From Our Partners